Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Net Income (2021 - 2025)

Coeptis Therapeutics Holdings has reported Net Income over the past 5 years, most recently at -$1.6 million for Q4 2025.

  • Quarterly results put Net Income at -$1.6 million for Q4 2025, up 46.11% from a year ago — trailing twelve months through Dec 2025 was -$12.3 million (down 12.87% YoY), and the annual figure for FY2025 was -$12.3 million, down 12.87%.
  • Net Income for Q4 2025 was -$1.6 million at Coeptis Therapeutics Holdings, up from -$2.9 million in the prior quarter.
  • Over the last five years, Net Income for COEPW hit a ceiling of -$100001.0 in Q3 2021 and a floor of -$19.2 million in Q1 2022.
  • Median Net Income over the past 5 years was -$3.1 million (2023), compared with a mean of -$4.8 million.
  • Peak annual rise in Net Income hit 78.43% in 2022, while the deepest fall reached 13634.12% in 2022.
  • Coeptis Therapeutics Holdings' Net Income stood at -$13.6 million in 2021, then skyrocketed by 78.43% to -$2.9 million in 2022, then dropped by 27.61% to -$3.8 million in 2023, then rose by 19.81% to -$3.0 million in 2024, then surged by 46.11% to -$1.6 million in 2025.
  • The last three reported values for Net Income were -$1.6 million (Q4 2025), -$2.9 million (Q3 2025), and -$4.3 million (Q2 2025) per Business Quant data.